Clinical Trials Logo

Chronic Kidney Disease clinical trials

View clinical trials related to Chronic Kidney Disease.

Filter by:

NCT ID: NCT02987465 Completed - Clinical trials for Cardiovascular Diseases

Evaluating the Effect of Standard-of-care Erythropoiesis-stimulating Agents on Forearm Blood Flow in Nondialysis-dependent Subjects With Anaemia Associated With Chronic Kidney Disease.

OPERA-CKD
Start date: February 20, 2017
Phase:
Study type: Observational

In people diagnosed with chronic kidney disease (CKD) anaemia is a common problem and is often treated with EPO (Erythropoietin). One form of EPO used is Darbepoetin (Aranesp®). EPO is safe to use but it has been associated with a rise in blood pressure (BP) in some individuals. The reasons for this are not clear. To try to explain this, this study will look at how EPO affects certain substances in the blood that influence how blood vessels contract and relax. This will be conducted by infusing small amounts of Acetylcholine, BQ123 and Noradrenaline into the arm vessels of volunteers using an established method called Forearm blood flow (plethysmography). Volunteers recruited for this study will include CKD patients undergoing therapy with Darbepoetin as part of their normal NHS care as well as healthy people not on treatment, who will act as controls. This is an observational pilot study of changes in physiology before and after Darbepoetin. It will provide valuable data for a later study comparing Darbepoetin to novel agents which work via different pathways to treat anaemia.

NCT ID: NCT02981706 Completed - Clinical trials for Chronic Kidney Disease

Comparison of AVF Versus AVG in Elderly Patients Starting Dialysis

Start date: October 6, 2016
Phase: N/A
Study type: Interventional

This is a pilot, single-center, randomized trial of 90 subjects to evaluate complication rates and functional status decline in subjects age 65 years and older referred for vascular access placement. Subjects will be randomized to arteriovenous fistula (AVF) (n = 45) versus arteriovenous graft (AVG) (n = 45), placed in a vascular access monitoring protocol, and undergo measurements of functional status including gait speed, grip strength, and self-reported function over 6 months. The primary hypothesis to be tested is that AVF placement will result in a higher proportion of primary access failure as defined by a binary composite primary endpoint of an unsalvageable access or an immature access or a non-functional access measured at 6 months compared to AVG placement. In addition, the study will evaluate whether AVF placement and a greater number of access procedures will result in a greater decline in functional status as measured by the average change over 6 months in gait speed, grip strength, and self-reported function as assessed by the Disabilities in Arm, Shoulder and Hand Survey.

NCT ID: NCT02976220 Completed - Clinical trials for Chronic Kidney Disease

Health Outcomes Patient Education

HOPE
Start date: November 2016
Phase: N/A
Study type: Interventional

This study is designed to evaluate the feasibility of using digital-enabled education in clinical care in order to improve patient outcomes related to end-stage renal disease (ESRD). If effective, educational interventions could be used to improve the long-term survival of patients with chronic kidney disease (CKD) and to make clinical care for these patients more cost effective.

NCT ID: NCT02973607 Completed - Hypertension Clinical Trials

Effects of a Reduction in Renal Function on Cardiovascular Structure and Function

CRIB-DONOR II
Start date: May 23, 2017
Phase:
Study type: Observational

Chronic kidney disease (CKD) is present in 1 in 7 of the population and confers a high risk of cardiovascular disease. The pathophysiology of cardiovascular disease in CKD is poorly understood because CKD is always accompanied by confounding factors including the underlying disease process (e.g. diabetes mellitus, systemic vasculitis) and the consequences of CKD including hypertension, anaemia and inflammation. Nephrectomy in kidney donors causes a 30% reduction in renal function providing an ideal study population to measure prospectively the effects of reduced kidney function on the cardiovascular system. The CRIB-Donor study (ClinicalTrials.gov Identifier:NCT01028703) demonstrated adverse effects on cardiovascular structure and function at 12 months compared to controls including an increase in left ventricular mass. This proposal will measure the changes in cardiovascular structure and function, cardiovascular age and biochemical changes at 5 years providing information on the long term effects of reduced renal function.

NCT ID: NCT02970123 Completed - Clinical trials for Chronic Kidney Disease

Sit Less, Interact, Move More (SLIMM) Intervention for Sedentary Behavior in Chronic Kidney Disease (CKD)

SLIMM
Start date: December 2016
Phase: N/A
Study type: Interventional

Sedentary behavior is engaging in activities in the seated or lying position that barely raise the energy expenditure level and has emerged as an important risk factor for obesity, diabetes, cardiovascular disease and mortality. The primary hypothesis is that the Sit Less, Interact, Move More (SLIMM) intervention in Chronic Kidney Disease (CKD) will be effective in decreasing sedentary duration by increasing casual walking duration and thereby, increase physical activity energy expenditure.

NCT ID: NCT02964936 Completed - Clinical trials for Chronic Kidney Disease

A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia

Start date: January 11, 2017
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the efficacy and the safety when ASP1517 is intermittently administered in Erythropoiesis Stimulating Agent (ESA)-untreated non-dialysis chronic kidney disease patients with anemia.

NCT ID: NCT02946034 Completed - Clinical trials for Chronic Kidney Disease

Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C

Start date: February 1, 2017
Phase: Phase 4
Study type: Interventional

Open-label experimental trial of 12 weeks of Viekira Pak treatment ± ribavirin or Mavyret for adults with chronic kidney disease and hepatitis C.

NCT ID: NCT02945969 Completed - Clinical trials for Chronic Kidney Disease

Sodium Lowering and Urinary Protein Reduction Trial

SUPER
Start date: November 2016
Phase: Phase 3
Study type: Interventional

The proposed randomized controlled trial will test the effect of dietary sodium reduction on albuminuria in patients with proteinuric chronic kidney disease. Results from this study will clarify the role of dietary sodium reduction in management of patients with proteinuric chronic kidney disease and its potential to halt the progression of chronic kidney disease.

NCT ID: NCT02940860 Completed - Clinical trials for Chronic Kidney Disease

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

Start date: November 29, 2016
Phase: Phase 3
Study type: Interventional

Evaluation of safety and efficacy of iron isomaltoside/ferric derisomaltose compared with iron sucrose, in subjects with both non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anaemia (IDA).

NCT ID: NCT02937350 Completed - Clinical trials for Chronic Kidney Disease

Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease

CLEAR
Start date: March 1, 2017
Phase: Phase 1
Study type: Interventional

The goal of this study is to better understand vitamin D catabolism and how it is affected by CKD and race.